Extended Data Fig. 3: In vivo antitumour efficacy of Gluc25-S-aPD-L1 in CT2A tumour models. | Nature Biomedical Engineering

Extended Data Fig. 3: In vivo antitumour efficacy of Gluc25-S-aPD-L1 in CT2A tumour models.

From: Conjugation of glucosylated polymer chains to checkpoint blockade antibodies augments their efficacy and specificity for glioblastoma

Extended Data Fig. 3

a, Timeline schedule for the treatment of CT2A tumour models. b, Bioluminescence images of CT2A tumour-bearing mice treated with saline, native aPD-L1, and Gluc25-S-aPD-L1 (aPD-L1: 1.5 mg per kg, n = 5). c, Region-of-interest analysis of bioluminescence intensities from whole brain. d, Survival curves for treated and control mice (n = 5). Statistical significance was calculated by log-rank test.

Back to article page